Article

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer

2024-12-20

Abstract excerpt

<h4>ABSTRACT</h4> Resistance to endocrine therapy (ET) is common in estrogen receptor-positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient derived organoids. Vandetani...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 36820f8d-225b-5622-ae57-842afdde9836
DOI: 10.1101/2024.12.19.629395

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerDOI 10.1101/2024.12.19.629395Read

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian CancerSemantic proximity Read

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast CancerSemantic proximity Read

Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.Semantic proximity Read

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.Semantic proximity Read

Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase InhibitionSemantic proximity Read

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitorsSemantic proximity Read

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read

Targeting the Breast Cancer KinomeSemantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read